Lake Street Advisors Group LLC boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 10,660 shares of the company’s stock after buying an additional 508 shares during the period. Lake Street Advisors Group LLC’s holdings in AstraZeneca were worth $763,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in AZN. ICA Group Wealth Management LLC acquired a new stake in shares of AstraZeneca during the 4th quarter worth approximately $26,000. Parkside Financial Bank & Trust boosted its stake in AstraZeneca by 4,875.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 398 shares of the company’s stock valued at $26,000 after buying an additional 390 shares in the last quarter. Fairfield Bush & CO. acquired a new stake in AstraZeneca in the 1st quarter valued at $28,000. Syverson Strege & Co acquired a new stake in AstraZeneca in the 1st quarter valued at $30,000. Finally, Sunbelt Securities Inc. acquired a new stake in AstraZeneca in the 1st quarter valued at $33,000. 15.68% of the stock is owned by institutional investors.
Analyst Ratings Changes
Several analysts recently commented on AZN shares. Erste Group Bank reaffirmed a “hold” rating on shares of AstraZeneca in a research note on Friday, September 8th. StockNews.com started coverage on AstraZeneca in a research note on Thursday, October 5th. They issued a “strong-buy” rating on the stock. Finally, Jefferies Financial Group raised AstraZeneca from a “hold” rating to a “buy” rating in a research note on Monday, September 25th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $103.00.
AstraZeneca Trading Up 0.5 %
Shares of AZN stock traded up $0.33 on Friday, reaching $64.13. 3,967,638 shares of the stock were exchanged, compared to its average volume of 5,935,447. The stock has a market cap of $198.79 billion, a PE ratio of 33.75, a P/E/G ratio of 1.28 and a beta of 0.51. AstraZeneca PLC has a one year low of $61.73 and a one year high of $76.56. The company has a debt-to-equity ratio of 0.60, a current ratio of 0.79 and a quick ratio of 0.60. The stock has a 50 day moving average price of $65.77 and a 200 day moving average price of $69.04.
AstraZeneca (NASDAQ:AZN – Get Free Report) last released its earnings results on Wednesday, November 8th. The company reported $0.87 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.03. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $11.55 billion. AstraZeneca had a return on equity of 30.30% and a net margin of 13.10%. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.84 earnings per share. Equities research analysts forecast that AstraZeneca PLC will post 3.64 EPS for the current fiscal year.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, andcommercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Five stocks we like better than AstraZeneca
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 11/13 – 11/17
- How to Invest in Grocery Stores
- 3 large caps with red hot RSIs with upside
- What is a Non-Fungible Token (NFT)? Definition and How it Works
- Johnson Controls International: Nothing but upside for investors
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.